Silence Therapeutics Plc ADR (SLN)

$6.91 -0.44 (-5.99%)
Market Cap 325.92M
Revenue (ttm) 560,000.00
Net Income (ttm) -88.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -15,823.21%
Debt to Equity Ratio 0.00
Volume 645,300
Avg Vol 269,742
Day's Range N/A - N/A
Shares Out 47.23M
Stochastic %K 81%
Beta 1.32
Analysts Strong Sell
Price Target $32.80

Company Profile

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treat...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 3457 6900
Address:
72 Hammersmith Road, London, United Kingdom
Redred67850
Redred67850 Mar. 17 at 2:44 PM
$SLN hi
0 · Reply
topstockalerts
topstockalerts Mar. 16 at 4:17 PM
$SLN Waking up now after holding support. Price is pushing higher with steady demand. Momentum traders are paying attention 👀.
0 · Reply
Rampagee
Rampagee Mar. 16 at 12:22 PM
$SLN
0 · Reply
LIGator
LIGator Mar. 12 at 5:02 PM
$SLN 💥 52 week high hit $7.79. Expanded the chart to two years and you can see $17-24. Something is going on.
0 · Reply
yft212
yft212 Mar. 11 at 7:30 PM
$SLN I'm hoping for an update (maybe a partnership announcement) on zerlasiran.
0 · Reply
topstockalerts
topstockalerts Mar. 11 at 5:27 PM
$SLN Looks like it wants higher prices. Buyers keep stepping in. This trend is still alive 📈.
0 · Reply
zbos
zbos Mar. 11 at 3:50 PM
$SLN back to $20 hopefully
0 · Reply
yft212
yft212 Mar. 11 at 3:35 PM
$SLN
0 · Reply
LIGator
LIGator Mar. 9 at 1:46 PM
$SLN this stock is acting so much better than it should be. Something is going on behind the scenes.
0 · Reply
ChuckNazty
ChuckNazty Mar. 7 at 1:36 PM
$SLN https://www.zacks.com/stock/news/2879423/wall-street-analysts-see-a-467-47-upside-in-silence-therapeutics-sln-can-the-stock-really-move-this-high?cid=CS-STOCKTWITS-HL-tale_of_the_tape%7Cconsensus_price_target-2879423&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_551_2879423 Zack’s is the worst!! The entire “article “ is an explanation of what a price target is with one “analyst “ thinking that SLN could go to $75 Motley and Zack are just pump and dump companies who write “articles “
0 · Reply
Latest News on SLN
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 5, 2026, 7:30 AM EST - 12 days ago

Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

Silence Therapeutics Announces Leadership Changes

Dec 15, 2025, 8:13 AM EST - 3 months ago

Silence Therapeutics Announces Leadership Changes

Silence Therapeutics: Divesiran Targets High-Burden PV

Nov 18, 2025, 6:03 AM EST - 4 months ago

Silence Therapeutics: Divesiran Targets High-Burden PV

Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Nov 12, 2025, 8:00 AM EST - 4 months ago

Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:30 AM EST - 4 months ago

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

Oct 23, 2025, 7:30 AM EDT - 5 months ago

Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

Silence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 10:01 PM EDT - 6 months ago

Silence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Silence Therapeutics to Participate in September Investor Conferences

Sep 2, 2025, 8:00 AM EDT - 7 months ago

Silence Therapeutics to Participate in September Investor Conferences

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 7, 2025, 7:30 AM EDT - 7 months ago

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

Jun 12, 2025, 4:01 PM EDT - 9 months ago

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 8:00 AM EDT - 11 months ago

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025, 7:45 AM EDT - 11 months ago

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

Mar 5, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 11:59 AM EST - 1 year ago

Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 7:30 AM EST - 1 year ago

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

Feb 13, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

Top 3 Health Care Stocks That May Explode In Q4

Dec 18, 2024, 7:46 AM EST - 1 year ago

Top 3 Health Care Stocks That May Explode In Q4

OLMA

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

Dec 9, 2024, 7:30 AM EST - 1 year ago

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

Nov 19, 2024, 3:34 PM EST - 1 year ago

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

Top 3 Health Care Stocks You'll Regret Missing In Q4

Nov 19, 2024, 7:52 AM EST - 1 year ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

AMRN TERN

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Nov 18, 2024, 2:30 PM EST - 1 year ago

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Nov 13, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy'

Sep 8, 2024, 9:13 AM EDT - 1 year ago

Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy'

Silence: Additional siRNA Drug Data Leads To Next Stages Of Development

Sep 5, 2024, 2:18 PM EDT - 1 year ago

Silence: Additional siRNA Drug Data Leads To Next Stages Of Development

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 15, 2024, 7:30 AM EDT - 1 year ago

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Jun 27, 2024, 7:30 AM EDT - 1 year ago

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration

Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results

Jun 21, 2024, 2:31 PM EDT - 1 year ago

Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

Jun 20, 2024, 7:30 AM EDT - 1 year ago

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

Silence Therapeutics to Present at Jefferies Global Healthcare Conference

May 30, 2024, 8:30 AM EDT - 1 year ago

Silence Therapeutics to Present at Jefferies Global Healthcare Conference

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

May 16, 2024, 8:30 AM EDT - 1 year ago

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Apr 30, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

Apr 29, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Apr 8, 2024, 11:48 AM EDT - 2 years ago

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 10:01 AM EDT - 2 years ago

Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Mar 13, 2024, 7:05 AM EDT - 2 years ago

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Mar 13, 2024, 7:00 AM EDT - 2 years ago

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Feb 28, 2024, 8:00 AM EST - 2 years ago

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look

Feb 24, 2024, 8:53 PM EST - 2 years ago

Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Feb 23, 2024, 8:00 AM EST - 2 years ago

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Feb 5, 2024, 8:00 AM EST - 2 years ago

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 7:00 AM EST - 2 years ago

Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

Dec 1, 2023, 7:00 AM EST - 2 years ago

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Nov 14, 2023, 7:00 AM EST - 2 years ago

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Nov 8, 2023, 7:00 AM EST - 2 years ago

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Nov 1, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Silence Therapeutics to Participate in Fireside Chat at Chardan's 7th Annual Genetic Medicines Conference

Sep 26, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics to Participate in Fireside Chat at Chardan's 7th Annual Genetic Medicines Conference

Redred67850
Redred67850 Mar. 17 at 2:44 PM
$SLN hi
0 · Reply
topstockalerts
topstockalerts Mar. 16 at 4:17 PM
$SLN Waking up now after holding support. Price is pushing higher with steady demand. Momentum traders are paying attention 👀.
0 · Reply
Rampagee
Rampagee Mar. 16 at 12:22 PM
$SLN
0 · Reply
LIGator
LIGator Mar. 12 at 5:02 PM
$SLN 💥 52 week high hit $7.79. Expanded the chart to two years and you can see $17-24. Something is going on.
0 · Reply
yft212
yft212 Mar. 11 at 7:30 PM
$SLN I'm hoping for an update (maybe a partnership announcement) on zerlasiran.
0 · Reply
topstockalerts
topstockalerts Mar. 11 at 5:27 PM
$SLN Looks like it wants higher prices. Buyers keep stepping in. This trend is still alive 📈.
0 · Reply
zbos
zbos Mar. 11 at 3:50 PM
$SLN back to $20 hopefully
0 · Reply
yft212
yft212 Mar. 11 at 3:35 PM
$SLN
0 · Reply
LIGator
LIGator Mar. 9 at 1:46 PM
$SLN this stock is acting so much better than it should be. Something is going on behind the scenes.
0 · Reply
ChuckNazty
ChuckNazty Mar. 7 at 1:36 PM
$SLN https://www.zacks.com/stock/news/2879423/wall-street-analysts-see-a-467-47-upside-in-silence-therapeutics-sln-can-the-stock-really-move-this-high?cid=CS-STOCKTWITS-HL-tale_of_the_tape%7Cconsensus_price_target-2879423&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_551_2879423 Zack’s is the worst!! The entire “article “ is an explanation of what a price target is with one “analyst “ thinking that SLN could go to $75 Motley and Zack are just pump and dump companies who write “articles “
0 · Reply
focafoca99
focafoca99 Mar. 5 at 4:38 PM
$SLN I’m watching if this filing tightens the story enough to draw sustained volume
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 4 at 1:13 PM
$SLN RSI: 72.83, MACD: 0.0935 Vol: 0.47, MA20: 4.94, MA50: 5.42 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
InfernoWyrm
InfernoWyrm Mar. 2 at 7:00 PM
|@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of the traders on this platform. If you’re not paying attention yet, you’re missing out. Go give him a follow it’s completely free and only takes a second 💎 ~ $LASR $SLN $PURR $OCUL ~ waching closely for more!
0 · Reply
LIGator
LIGator Mar. 2 at 3:41 PM
$SLN pleasantly surprising today.
0 · Reply
InfernoWyrm
InfernoWyrm Feb. 24 at 1:08 AM
;@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of the traders on this platform. If you’re not paying attention yet, you’re missing out. Go give him a follow. It’s completely free and only takes a second 💎 $SLN $CGON $GUTS $VRE 2
1 · Reply
yft212
yft212 Feb. 19 at 7:02 PM
$SLN
0 · Reply
jacksonjohn750
jacksonjohn750 Feb. 18 at 5:10 PM
$SLN what are the milestones for 2026? We expecting a run p to? Topline Phase 2 SANRECO trial results expected in Q3 2026
0 · Reply
JaredMcpherson121
JaredMcpherson121 Feb. 18 at 1:22 PM
$SLN Clinical-stage biotech with funding risk.
0 · Reply
ObscureCandle
ObscureCandle Feb. 18 at 7:35 AM
$SLN Silence Therapeutics develops RNAi therapies, facing early-stage platform technology with partnership-dependent valuation [citation:historical].
0 · Reply
LIGator
LIGator Feb. 9 at 8:06 PM
$SLN new 13d filed. Lombard Odier had almost 2 million shares of the ADS that’s 4.2% of the company.
0 · Reply
lars4
lars4 Feb. 8 at 5:26 PM
$SLN Why can I with Schwab only buy shares from broker call and not on Thinkorswim platform?
0 · Reply
LIGator
LIGator Jan. 27 at 4:59 PM
$GLSI trimmed a few shares that I bought last week at 23.81 so I could add more $SLN at $5.26. 2026 will be the year for both.
0 · Reply